Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations

Inclusion Criteria:

1. Morphologically confirmed NSCLC with or without actionable genomic alterations (AGA,i.e. EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, ERBB2 (HER2), or KRAS)

2. Age ≥18 years at the time of NSCLC diagnosis;

3. Locally advanced or metastatic disease defined as incident stage IIIB/IIIC/IV NSCLCor stage I-IIIA then progressed to stage IIIB-IV disease and not eligible forcurative-intent treatment (the date of progression is included in the database);

4. Available data on at least one line of systemic therapy for advanced/metastaticdisease within the period since January 2022 until January 2025;

5. Patients may be alive or deceased at the time of medical record abstraction

Exclusion Criteria:

1. Patients participated or participating in clinical trials or any early accessprogram within period since the index date until the end of study period;

2. Diagnosis of another cancer (except for melanoma/skin cancer) at or within 5 yearsprior to NSCLC diagnosis or any ongoing systemic anti-cancer therapy regimen at thetime of NSCLC diagnosis